Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$462.88 USD

462.88
706,669

-0.27 (-0.06%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $462.85 -0.03 (-0.01%) 5:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know

Vertex Pharmaceuticals (VRTX) closed at $215.15 in the latest trading session, marking a +0.4% move from the prior day.

bluebird (BLUE) Up on Updated Findings in LentiGlobin's SCD Study

bluebird (BLUE) gains following the updated findings from the reported case of AML in LentiGlobin for SCD gene therapy program.

Vertex (VRTX) Type I Diabetes Candidate Clinical Study Begins

Vertex (VRTX) begins early-stage clinical study on cellular therapy, VX-880 for type-I diabetes. FDA also grants Fast Track status to the candidate.

Kaustav Ghosh headshot

5 Stocks to Watch Amid Continued Expansion in the Biotech Industry

The biotech industry seems poised for further growth due to factors like advancements in drug research and faster regulatory process, making it wise to look at names like AbbVie (ABBV) and Novavax (NVAX)

Vertex (VRTX) Down 2.4% Since Last Earnings Report: Can It Rebound?

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Fall Y/Y

CRISPR Therapeutics (CRSP) misses estimates for both earnings and revenues in the fourth quarter of 2020. Focus on pipeline development.

CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?

On CRISPR Therapeutics' (CRSP) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its lead gene-editing candidate, CTX001.

Biotech Stock Roundup: AMGN, VRTX Q4 Results, SAVA's Encouraging Drug Data & More

Earnings of leading biotechs like Amgen (AMGN) and Vertex (VRTX) and vaccine updates from Novavax (NVAX) were some of the highlights of the biotech sector last week.

Vertex (VRTX) Q4 Earnings Miss, Revenues Beat Estimates

Vertex (VRTX) reports missing earnings estimates in the fourth quarter of 2020, while revenues surpass the same. The company provides revenues guidance for 2021.

Mark Vickery headshot

Markets Snap Back into Bullish Territory

The Nasdaq led the way, +2.55%, followed by the small-cap Russell 2000, which snapped a five-session losing streak.

Vertex Pharmaceuticals (VRTX) Lags Q4 Earnings Estimates

Vertex (VRTX) delivered earnings and revenue surprises of -5.28% and 2.91%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Markets Await Economic and Earnings Data

Markets Await Economic and Earnings Data

Mark Vickery headshot

Another Big Week for Q4 Earnings, Econ News; ON Semi Beats

Q4 earnings season keeps going full-throttle this week, with lots of household names reporting quarterly earnings.

Can Biogen (BIIB) Keep the Earnings Streak Alive in Q4?

Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports fourth-quarter earnings.

Zacks.com featured highlights include: Crocs, AGCO, Meritage Homes and Vertex Pharmaceuticals

Zacks.com featured highlights include: Crocs, AGCO, Meritage Homes and Vertex Pharmaceuticals

Will Strong Veklury Sales Aid Gilead's (GILD) Q4 Earnings?

Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports fourth-quarter 2020 results.

Vertex's (VRTX) IND for Type I Diabetes Drug Gets FDA Clearance

Vertex (VRTX) gets FDA clearance for the investigational new drug application of VX-880, for the potential treatment of type I diabetes.

Why Earnings Season Could Be Great for Vertex (VRTX)

Vertex (VRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Sumit Singh headshot

4 Stocks That Flaunt an Impressive Interest Coverage Ratio

A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Crocs (CROX), AGCO Corporation (AGCO), Meritage Homes (MTH) and Vertex Pharmaceuticals (VRTX) are sound enough to meet financial obligations.

5 Big Pharma/Biotech Stocks Set to Trump Q4 Earnings Estimates

Let us take a look at some drug/biotech stocks including Sanofi (SNY) and Merck (MRK) that are poised to beat fourth-quarter earnings estimates.

Will Trikafta Drive Vertex's (VRTX) Revenues in Q4 Earnings?

On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales performance of its triple combo CF drug Trikafta.

Vertex's (VRTX) Trikafta NDA Gets Priority Review by FDA

Vertex's (VRTX) sNDA seeking approval for Trikafta to treat cystic fibrosis in children has been accepted by the FDA.

Biotech Stock Roundup: Coronavirus Updates From REGN, MRNA, & Other Updates

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Moderna (MRNA) and Exelixis (EXEL).

The Zacks Analyst Blog Highlights: NIKE, Amgen, Morgan Stanley, Vertex Pharma and Moderna

The Zacks Analyst Blog Highlights: NIKE, Amgen, Morgan Stanley, Vertex Pharma and Moderna

Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $241.31, moving +1.57% from the previous trading session.